Try

Phathom Pharmaceuticals Inc. Common Stock

PHATUnited States

5 filed reports · 227 financial concepts · 4 earnings calls · 0 media appearances

Filed reports

5 reports · Jun 2025 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR4974Jun 2025 to Jun 2026
Annual · 10-KSEC EDGAR1562Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q210-QJun 30, 2026Jul 30, 2026385Open
FY2026 Q110-QMar 31, 2026Apr 30, 2026237Open
FY202510-KDec 31, 2025Feb 26, 2026562Open
FY2025 Q310-QSep 30, 2025Oct 30, 2025249Open
FY2025 Q210-QJun 30, 2025Aug 7, 2025103Open

Financial data

227 concepts · 1,536 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial214 concepts · 1,417 facts · Mar 2024 to Jun 2026

  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value12 · Mar 2024 to Jun 2026
  • Net income loss12 · Mar 2024 to Jun 2026
  • Stockholders equity (US GAAP)12 · Mar 2024 to Jun 2026
  • Treasury stock common shares12 · Mar 2024 to Jun 2026
  • Allocated share based compensation expense11 · Jun 2024 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations11 · Jun 2024 to Jun 2026
  • Cost of revenue (US GAAP)11 · Jun 2024 to Jun 2026
  • Defined contribution plan cost recognized11 · Jun 2024 to Jun 2026
  • Expenses incurred related to purchase commitments11 · Jun 2024 to Jun 2026
  • Gross profit (US GAAP)11 · Jun 2024 to Jun 2026
  • Interest expense nonoperating11 · Jun 2024 to Jun 2026
  • Interest expense with revenue interest finance liability11 · Jun 2024 to Jun 2026
  • Investment income interest11 · Jun 2024 to Jun 2026
  • Nonoperating income expense11 · Jun 2024 to Jun 2026
  • Operating expenses (US GAAP)11 · Jun 2024 to Jun 2026
  • Operating income loss11 · Jun 2024 to Jun 2026
  • Operating lease expense11 · Jun 2024 to Jun 2026
  • Other nonoperating income expense11 · Jun 2024 to Jun 2026
  • Purchase commitment remaining minimum amount committed11 · Jun 2025 to Jun 2026
  • Research and development expense11 · Jun 2024 to Jun 2026
  • Revenue11 · Jun 2024 to Jun 2026
  • Selling general and administrative expense11 · Jun 2024 to Jun 2026
  • Short term lease cost11 · Jun 2024 to Jun 2026
  • 401(k) matching contribution, shares10 · Sep 2024 to Jun 2026

Segment10 concepts · 100 facts · Sep 2024 to Jun 2026

  • Cost of revenue (US GAAP)10 · Sep 2024 to Jun 2026
  • General and administrative expense (US GAAP)10 · Sep 2024 to Jun 2026
  • Interest expense nonoperating10 · Sep 2024 to Jun 2026
  • Investment income interest10 · Sep 2024 to Jun 2026
  • Net income loss10 · Sep 2024 to Jun 2026
  • Other nonoperating income expense10 · Sep 2024 to Jun 2026
  • Research and development10 · Sep 2024 to Jun 2026
  • Revenue10 · Sep 2024 to Jun 2026
  • Selling and marketing expense (US GAAP)10 · Sep 2024 to Jun 2026
  • Share based compensation10 · Sep 2024 to Jun 2026

Product2 concepts · 11 facts · Sep 2024 to Jun 2026

  • Revenue10 · Sep 2024 to Jun 2026
  • Percentage of total revenue represented by product1 · Dec 2025

Geography1 concepts · 8 facts · Sep 2025 to Jun 2026

  • Operating lease number of option to extend8 · Sep 2025 to Jun 2026

Segments

119 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments1 member · 100 facts

  • Reportable Segment Aggregation Before Other Operating100 · Sep 2024 to Jun 2026

Product or service1 member · 11 facts

  • Voquezna Product11 · Sep 2024 to Jun 2026

Statement geographical2 members · 8 facts

  • NJ5 · Sep 2025 to Jun 2026
  • IL3 · Dec 2025 to Jun 2026

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

4 calls · Oct 2025 to Jul 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q2Jul 30, 2026
  • FY2026 Q1Apr 30, 2026
  • FY2025 Q4Feb 26, 2026
  • FY2025 Q3Oct 30, 2025

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

Phathom Pharmaceuticals Inc. Common Stock (PHAT) data · FactIQ